Bile Duct Cancer: Clinical Trials

28 trials for Bile Duct Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 7 unknown, 6 recruiting, 5 terminated. 28 Phase 2, 4 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 228Completed 7, Unknown 7, Recruiting 6, Terminated 5, Active not recruiting 2, Not yet recruiting 1
Phase 14Completed 2, Recruiting 2
Phase 33Unknown 2, Completed 1

Follow Bile Duct Cancer: new trials by email Literature Review of Bile Duct Cancer trials Research Report on Bile Duct Cancer

Trials (filtered) newest first · largest first

All 28 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer
Gemcitabin, Cisplatin and Durvalumab, Biliary Radiofrequency Ablation, Endoscopic Retrograde Cholangio-Pancreatography with stenting - Bile Duct Cancer
Phase 2RecruitingInsel Gruppe AG, University Hospital Bern362026-05-202026-05-26
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
Stereotactic Body Radiotherapy (SBRT), Tislelizumab, Gemcitabine - Cholangiocarcinoma, Hilar Cholangiocarcinoma
Phase 2RecruitingJinbo Yue382025-07-012026-10-15
Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors
Utidelone Capsule 60mg/m2/d, Utidelone capsule 75mg/m2, Utidelone Capsule - Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer
Phase 2Not yet recruitingBeijing Biostar Pharmaceuticals Co., Ltd.1002024-12-012024-12-12
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
oxaliplatin, capecitabine, Keytruda - Biliary Cancer, Bile Duct Cancer
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)602024-05-082026-10-30
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
Gemcitabine, Cisplatin, Zimberelimab - Biliary Tract Carcinoma, Cholangiocarcinoma
Phase 2Active not recruitingNataliya Uboha332024-03-082026-08-17
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Gemcitabine, Cisplatin, Durvalumab - Bile Duct Cancer, Cholangiocarcinoma
Phase 2RecruitingBeth Israel Deaconess Medical Center302024-02-132026-04-22
Combined Treatment of Treated Bile Duct Cancer
envolizumab , sovalteinib - Bile Duct Cancer
Phase 2UnknownZhejiang Cancer Hospital302023-07-012023-06-22
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
certepetide, Durvalumab, Cisplatin - Cholangiocarcinoma, Gallbladder Cancer
Phase 2CompletedLisata Therapeutics, Inc.662023-05-132026-09-28
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
Dexamethasone, PDS01ADC, Intera 3000 Hepatic Artery Infusion Pump (HAIP) - Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc)
Phase 2RecruitingNational Cancer Institute (NCI)702022-10-242026-10-16
Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
Trametinib, Hydroxychloroquine - Bile Duct Cancer, Biliary Cancer
Phase 2TerminatedNational Cancer Institute (NCI)22022-02-152023-08-21
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Atezolizumab, Tivozanib - Bile Duct Cancer, Gall Bladder Cancer
Phase 1 / Phase 2RecruitingUniversity of Florida292021-12-072026-07-13
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Seribantumab - Locally Advanced Solid Tumor, Metastatic Solid Tumor
Phase 2TerminatedElevation Oncology542020-09-292025-04-03
DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer
AZD6738, Durvalumab, Olaparib - Bile Duct Cancer, Chemotherapy Effect
Phase 2UnknownSeoul National University Hospital742020-06-252024-04-19
AZD6738 Plus Durvalumab in Biliary Tract Cancer
AZD6738, Durvalumab - Bile Duct Cancer, Chemotherapy Effect
Phase 2UnknownSeoul National University Hospital262020-06-252024-04-19
Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma
Trifluridine/Tipiracil - Cholangiocarcinoma, Bile Duct Cancer
Phase 2TerminatedSunnybrook Health Sciences Centre82019-12-112022-12-01
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
A166 - HER2-positive Breast Cancer, HER2 Gene Mutation
Phase 1 / Phase 2CompletedKlus Pharma Inc.492018-07-162023-08-03
Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma
Melphalan/HDS, Cisplatin and Gemcitabine - Bile Duct Cancer, Intrahepatic Cholangiocarcinoma
Phase 2 / Phase 3UnknownDelcath Systems Inc.2952018-04-102022-03-24
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)
Pembrolizumab (MK-3475), Oxaliplatin, Capecitabine - Biliary Tract Neoplasms, Cholangiocarcinoma
Phase 2CompletedNational Cancer Institute (NCI)112017-06-142021-12-03
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
INT230-6, anti-PD-1 antibody, anti-CTLA-4 antibody - Breast Cancer, Head and Neck Cancer
Phase 1 / Phase 2CompletedIntensity Therapeutics, Inc.1112017-02-092025-02-27
A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)
Durvalumab, Tremelimumab, Trans-arterial Catheter Chemoembolization (TACE) - Biliary Tract Neoplasms, Liver Cancer
Phase 2CompletedNational Cancer Institute (NCI)542016-07-052023-03-28

Showing 20 of 28. Sign in to see all of them.

Narrower conditions

Bile Duct Neoplasms (28)  ·  Cholangiocarcinoma (17)  ·  Gallbladder Neoplasms (8)  ·  Biliary Tract Neoplasms (6)  ·  Liver Neoplasms (6)  ·  Breast Neoplasms (4)  ·  Colorectal Neoplasms (4)  ·  Ovarian Neoplasms (4)  ·  Carcinoma, Hepatocellular (3)  ·  Head and Neck Neoplasms (3)  ·  Lung Neoplasms (3)  ·  Pancreatic Neoplasms (3)  ·  Prostatic Neoplasms (3)  ·  Sarcoma (3)  ·  Colonic Neoplasms (2)

Broader conditions

Bile Duct Diseases (28)  ·  Biliary Tract Diseases (28)  ·  Digestive System Diseases (28)  ·  Digestive System Neoplasms (28)  ·  Neoplasms by Site (28)  ·  Neoplasms (27)  ·  Biliary Tract Neoplasms (22)  ·  Neoplasms by Histologic Type (20)  ·  Neoplasms, Glandular and Epithelial (20)  ·  Adenocarcinoma (19)  ·  Carcinoma (19)  ·  Gallbladder Diseases (8)  ·  Endocrine Gland Neoplasms (7)  ·  Endocrine System Diseases (7)  ·  Gastrointestinal Diseases (7)

Interventions

Cisplatin (8)  ·  Gemcitabine (8)  ·  durvalumab (6)  ·  Oxaliplatin (4)  ·  pembrolizumab (4)  ·  Capecitabine (3)  ·  Fluorouracil (3)  ·  Radiosurgery (2)  ·  ceralasertib (2)  ·  1-phenyl-3,3-dimethyltriazene (1)  ·  Carboplatin (1)  ·  Cryosurgery (1)  ·  Dexamethasone (1)  ·  Erlotinib Hydrochloride (1)  ·  Floxuridine (1)

Sponsors

National Cancer Institute (NCI) (5)  ·  Seoul National University Hospital (2)  ·  Beijing Biostar Pharmaceuticals Co., Ltd. (1)  ·  Beth Israel Deaconess Medical Center (1)  ·  Centre Hospitalier Universitaire de Saint Etienne (1)  ·  Charite University, Berlin, Germany (1)  ·  Delcath Systems Inc. (1)  ·  Elevation Oncology (1)  ·  Insel Gruppe AG, University Hospital Bern (1)  ·  Intensity Therapeutics, Inc. (1)  ·  Jinbo Yue (1)  ·  Klus Pharma Inc. (1)  ·  Lisata Therapeutics, Inc. (1)  ·  Massachusetts General Hospital (1)  ·  Merck Sharp & Dohme LLC (1)

Countries

United States (17)  ·  Canada (3)  ·  South Korea (3)  ·  China (2)  ·  Australia (1)  ·  France (1)  ·  Germany (1)  ·  Switzerland (1)

Top investigators

Tim F Greten, M.D. (4)  ·  Andrea Bullock, MD, MPH (1)  ·  Anthony El-Khoueiry, M.D. (1)  ·  Anthony J. Olszanski, M.D., RPh (1)  ·  Ari D Baron, MD (1)  ·  Bert Hildebrandt, MD (1)  ·  Bo Zhang (1)  ·  Brian Schwartz, M.D. (1)  ·  Daniel T Chang (1)  ·  Giles F Whalen, M.D. (1)  ·  Hanno Riess, MD, PhD (1)  ·  Jean-Marc Phelip, PhD (1)  ·  Jens Ricke, MD, PhD (1)  ·  Jinbo Yue (1)  ·  Jonathan M Hernandez, M.D. (1)

Results publications

PMID 28192597, PMID 30943124, PMID 31682550, PMID 31980466, PMID 32359091, PMID 32919526, PMID 33836153, PMID 34662180, PMID 34990208, PMID 35114169, PMID 35274717, PMID 35361487, PMID 35588692, PMID 35680043, PMID 35777186, PMID 35835611, PMID 36399037, PMID 36748723, PMID 38205877, PMID 38989414, PMID 39965889, PMID 39979665, PMID 40121391, PMID 40812353, PMID 41428976, PMID 41816011, PMID 41920388, PMID 42365236

NIH funding

2015 (2), 2023 (1)